Arul Priya M¹*, Manoj Abrahmam Manoharlal² and MK Franklin Shaju³

¹MPT-Research Scholar, KG College of Physiotherapy, Coimbatore-641035, Affiliated to The Tamil Nadu Dr. M.G.R Medical University, Chennai-600032, India
²Principal, KG College of Physiotherapy, Coimbatore-641035, Affiliated to The Tamil Nadu Dr. M.G.R Medical University, Chennai-600032, India
³Principal, R.V.S. College of Physiotherapy, Coimbatore-641402, Affiliated to The Tamil Nadu Dr. M.G.R Medical University, Chennai-600032, India

*Corresponding Author: Arul Priya M, MPT-Research Scholar, KG College of Physiotherapy, Coimbatore-641035, Affiliated to The Tamil Nadu Dr. M.G.R Medical University, Chennai-600032, India.

Received: May 19, 2026; Published: July 02, 2026

Background: In India the prevalence of diabetes is high and continues to increase at an alarming rate. Mild cognitive impairment is a common complication of Type 2 Diabetes Mellitus (T2DM), which might have a threatening effect on the functional ability of patients if left unnoticed and untreated. In India there are diverse cultural practices and different languages spoken across the region. It is very essential to have a screening test that is easy, practical, valid and also subtle to identify the sensitive cognitive domains that are affected in type 2 diabetes and that has different versions (Languages) more suitable for various language speaking population in India. Montreal cognitive assessment is one of the available screening tools that is widely used to detect cognitive impairment. This systematic review explores how Montreal cognitive assessment (MoCA )can help in identifying Mild cognitive impairment (MCI) and how sensitive it is to identify the key domains of cognition that may be affected in T2DM in Indian population.

Method: A thorough search was carried out using the electronic databases of PubMed, Embase and google scholar for studies published between 2016 and 2026 to identify the studies that used Montreal cognitive assessment (MoCA) alone or with other tool to identify MCI in T2DM patients in India. After careful reading and reviewing; about 14 articles were included for the review process. A systematic approach was utilized to summarize the key findings from the selected 14 studies by identifying common themes like region of the study, mean age of the sample, mean MoCA score, common domains of cognition affected, version of MoCA used and gender differences in the prevalence of MCI in type 2 diabetes.

Conclusion: The reviewed literature showed Montreal cognitive assessment (MoCA) can be used as a screening tool in the Indian hospitals with regional version to detect mild cognitive impairment and that can have a positive impact on the health outcomes of type 2 diabetics if cognitive impairment is diagnosed at an early stage.

Keywords: Type 2 Diabetes Mellitus; Mild Cognitive Impairment; Montreal Cognitive Assessment Tool; Indian Population

Abbreviations: T2DM: Type 2 Diabetes Mellitus; MoCA: Montreal Cognitive Assessment; MCI: Mild Cognitive Impairment.

References

1. International Diabetes Federation. “IDF Diabetes Atlas”. 11^th, International Diabetes Federation (2025).
2. Saeedi P., et al. “Global and Regional Diabetes Prevalence Estimates for 2019 and Projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9^th Edition”. Diabetes Research and Clinical Practice 157 (2019): 107843.
3. Teufel F., et al. “Global, Regional, and National Estimates of Undiagnosed Diabetes in Adults: Findings from the 2025 IDF Diabetes Atlas”. Diabetes Care3 (2026): 490-496.
4. Mohan V and M Tiwaskar. “The Unrelenting Epidemic of Diabetes in India: Do the Numbers Matter?” Journal of the Association of Physicians of India5 (2025): 12-13.
5. Newtonraj A and K S Kannan. “Time Series Forecasting and Projection of Diabetes Prevalence in India from 2023 to 2035: A Cross-Sectional Study”. Journal of Clinical and Diagnostic Research10 (2024): LC01-LC05. 
6. Lalithambika CV., et al. “Prevalence of Mild Cognitive Impairment in Type 2 Diabetes Mellitus and Its Correlation with Glycemic Control”. Journal of Clinical and Diagnostic Research3 (2025): OC01-OC05. 
7. Beckman J A and MA Creager. “Vascular Complications of Diabetes”. Circulation Research11 (2016): 1771-1785.
8. Aderinto N., et al. “The Impact of Diabetes in Cognitive Imppairment: A Review of Current Evidence and Prospects for Future Investigations”. Medicine43 (2023): e35557. 
9. Biessels G J and R A Whitmer. “Cognitive Dysfunction in Diabetes: How to Implement Emerging Guidelines”. Diabetologia1 (2020): 3-9. 
10. Koekkoek PS., et al. “Cognitive Function in Patients with Diabetes Mellitus: Guidance for Daily Care”. The Lancet Neurology3 (2015): 329-340.
11. Chakraborty S., et al. “Prevalence and Risk Factors of Mild Cognitive Impairment in Type 2 Diabetes Mellitus Patients: A Cross-Sectional Study from South India”. International Journal of Diabetes in Developing Countries3 (2021): 421-428.
12. Raghuveer Pracheth., et al. “Prevalence and Factors Associated with Cognitive Impairment among Persons with Type 2 Diabetes Mellitus: A Cross-Sectional Study in Medical College Hospitals of South India”. Clinical Epidemiology and Global Health 15 (2025): 101-107. 
13. Bhosale A., et al. “Mild Cognitive Impairment in Type 2 Diabetes Mellitus: Prevalence and Associated Factors in a Tertiary Care Hospital”. Indian Journal of Psychological Medicine1 (2025): 45-52.
14. Cao F., et al. “The Relationship Between Diabetes and Dementia Risk: A Meta-Analysis”. Diabetology and Metabolic Syndrome 16 (2024): 101.
15. Stanciu GD., et al. “Link Between Diabetes and Alzheimer’s Disease Due to the Shared Amyloid Aggregation and Deposition”. Journal of Clinical Medicine 9 (2020): 1713.
16. Liao X., et al. “Cognitive Impairment in Type 2 Diabetes: Global Trends and Diagnostic Approaches”. Biomedicines2 (2025): 473. 
17. Saedi E., et al. “Diabetes Mellitus and Cognitive Impairments”. World Journal of Diabetes 7 (2016): 412-422.
18. Aderinto N., et al. “The Impact of Diabetes in Cognitive Impairment”. Medicine43 (2023): e35557.
19. Pinto T C C., et al. “Is the Montreal Cognitive Assessment (MoCA) Screening Superior to the Mini-Mental State Examination (MMSE)?” International Psychogeriatrics4 (2019): 491-504.
20. Nasreddine Z S., et al. “The Montreal Cognitive Assessment (MoCA): A Brief Screening Tool for Mild Cognitive Impairment”. Journal of the American Geriatrics Society4 (2005): 695-699.
21. Bhosale U., et al. “Association Between Cognitive Impairment and Glycemic Control in Type 2 Diabetes”. International Journal of Current Pharmaceutical Research3 (2025): 45-48.
22. Vijay Anand R., et al. “Incidence of Cognitive Impairment Among Adults with Type II Diabetes Mellitus”. International Journal of Academic Medicine and Pharmacy2 (2023): 1646-1657.
23. Chatterjee, S., et al. “Prevalence and Pattern of Cognitive Dysfunction in Type-2 Diabetes”. Journal of Family Medicine and Primary Care2 (2025.
24. Chakraborty A., et al. “Age-Related Prevalence of Mild Cognitive Impairment in Type 2 Diabetes Mellitus”. Frontiers in Endocrinology 12 (2021): 798652.
25. Thomas P E., et al. “Validity and Reliability of Montreal Cognitive Assessment”. Indian Journal of Public Health Research and Development3 (2018): 173-177.
26. Gupta A., et al. “Validity of Montreal Cognitive Assessment to Detect Cognitive Impairment”. Diabetes Therapy5 (2024): 1155-1168.
27. Mishra R and S G Rajesh. “Association of Cognitive Impairment and Type 2 Diabetes Mellitus”. International Journal of Contemporary Medical Research12 (2019): L32-L36.
28. Pednekar S., et al. “Study of Mild Cognitive Impairment in Type 2 Diabetes Mellitus Patients”. International Journal of Research in Medical Sciences7 (2016): 2615-2618.
29. Ray S., et al. “Relationship Between Cognitive Impairment and Glycemic Management Using MoCA Score”. Medical Research Archives3 (2025).
30. Suvvari T K and C S Kali. “Association Between Type 2 Diabetes Mellitus and Cognitive Impairment”. Annals of Neurosciences1 (2026): 59-64.
31. Yerrapragada DB., et al. “Cognitive Dysfunction Among Adults with Type 2 Diabetes Mellitus”. Ochsner Journal3 (2019): 227-234.
32. Khullar S., et al. “Prevalence and Predictors of Cognitive Impairment in Type 2 Diabetes”. Journal of Social Health and Diabetes1 (2017): 47-53.
33. Ramani P N., et al. “Assessing Cognitive Impairment in Type 2 Diabetes Mellitus”. International Journal of Medicine and Public Health1 (2025): 1627-1633.
34. Perabathula SC., et al. “Cognitive Impairment in Type 2 Diabetes Mellitus”. Journal of YSR University of Health Sciences4 (2024): 317-322.
35. Kant S., et al. “Assessment of Cognitive Impairment Using ACE and MoCA”. IP Indian Journal of Neurosciences4 (2018): 185-190.
36. Kinattingal N., et al. “Prevalence of Cognitive Decline in Type 2 Diabetes Mellitus Patients”. Journal of Personalized Medicine3 (2023): 524.
37. Mishra R and S G Rajesh. “Association of Cognitive Impairment and Type 2 Diabetes Mellitus”. International Journal of Contemporary Medical Research12 (2019): L32-L36.
38. Panse R., et al. “Cognitive Impairments and Associated Risk Factors Among Diabetes Patients”. Indian Journal of Public Health Research and Development1 (2020): 193-198.
39. Godhasara SD and V Suthar. “Prevalence of Cognitive Impairment in Type II Diabetes Mellitus”. International Journal of Health Sciences and Research11 (2021): 136-142.
40. Varghese S M., et al. “Sweet Memories or Not? A Comparative Study on Cognitive Impairment in Diabetes Mellitus”. Frontiers in Public Health 10 (2022): 822062.

Citation

Citation: Arul Priya M., et al. “Montreal Cognitive Assessment Based Screening for Mild Cognitive Impairment in Indian Type 2 Diabetic Population: A Comprehensive Review of Current Evidence". Acta Scientific Medical Sciences 10.7 (2026): 39-47.

Copyright

Copyright: © 2026 Arul Priya M., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.